The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.

Autor:	Klassen SA; Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN., Senefeld JW; Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN., Johnson PW; Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL., Carter RE; Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL., Wiggins CC; Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN., Shoham S; Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD., Grossman BJ; Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO., Henderson JP; Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO; Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO., Musser J; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX; Center for Molecular and Translational Human Infectious Diseases, Houston Methodist Research Institute, Houston, TX; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY., Salazar E; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY., Hartman WR; Department of Anesthesiology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Icahn School of Medicine at Mount Sinai, New York, NY., Bouvier NM; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY., Liu STH; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY., Pirofski LA; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY., Baker SE; Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN., van Helmond N; Department of Anesthesiology, Cooper Medical School of Rowan University, Cooper University Health Care, Camden, NJ., Wright RS; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN; Director, Human Research Protection Program, Mayo Clinic, Rochester, MN., Fairweather D; Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL., Bruno KA; Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL., Wang Z; Evidence-Based Practice Center, Robert D. and Patricia E. Kern Center for Science of Health Care Delivery, Mayo Clinic, Rochester, MN., Paneth NS; Department of Epidemiology and Biostatistics, Michigan State University, East Lansing; Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing., Casadevall A; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD., Joyner MJ; Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN. Electronic address: joyner.michael@mayo.edu.
Jazyk:	angličtina
Zdroj:	Mayo Clinic proceedings [Mayo Clin Proc] 2021 May; Vol. 96 (5), pp. 1262-1275. Date of Electronic Publication: 2021 Feb 17.
DOI:	10.1016/j.mayocp.2021.02.008
Abstrakt:	To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose-response studies, and 96 case reports or case series. Studies published between January 1, 2020, and January 16, 2021, were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of randomized clinical trials and matched control data demonstrated that patients with COVID-19 transfused with convalescent plasma exhibited a lower mortality rate compared with patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized patients with COVID-19. (Copyright © 2021 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu